%L eprints949
%X As an alternative treatment in cancer therapy, there has been a growing interest in using helminths, such as Trichinella spiralis (T. spiralis), Echinococcus granulosus (E. granulosus), Toxocara canis (T. canis), and Taenia solium (T. solium). This study aimed to investigate the antigens and mechanisms that contribute to the anticancer properties of helminths, providing insights into how helminths may be used as a new and innovative treatment modality for cancer. The current review analyzed preclinical and clinical studies published between 2000 and 2023. The present study sought to obtain information on helminths, such as E. granulosus, T. spiralis, T. canis, and T. solium, to treat cancers of the breast, pancreas, melanoma, and leukemia by exploring databases, such as PubMed, Google Scholar, and Scopus. Studies focusing on helminth therapy against particular cancer types for in vitro and animal models were included. Several studies have shown the possibility of inhibiting breast, colon, melanoma, and leukemia tumor growth, inducing apoptosis, and modulating the tumor microenvironment with E. granulosus, T. spiralis, T. canis, and T. solium based on in vitro and animal models studies. Some studies have indicated that helminth therapy can improve survival rates, reduce tumor growth, and stimulate the immune system in cancer patients. A potential improvement in treatment outcomes can be used for combination therapies, such as antigen selection, immune profiling, and individualized approaches based on helminth therapy. Helminth therapy is an additional option for cancer treatment, emphasizing T. spiralis, E. granulosus, T. canis, and T. solium. These helminth antigens could modulate immune responses and directly cause cytotoxicity in cancer cells. © Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article�s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article�s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
%O Mashhad University of Medical Sciences, Mashhad, Iran; School of Health and Social Care, Swansea University, Wales, United Kingdom; Faculty of Medicine, Islamic Azad University, Mashhad Branch, Mashhad, Iran; Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
%V 13
%T Using Helminths to Fight Cancer: An Innovative Approach
%I SCIENCELINE
%A N. Ameli
%A A. Masoumi
%A M. Kerachi
%A N. Sheidaeimehneh
%A N.L. Khavidaki
%A M. Zamanian
%D 2023
%J World's Veterinary Journal
%K antigen 1; antigen 5; blood group B antigen; fluorouracil; parasite antigen; unclassified drug, antineoplastic activity; apoptosis; Article; breast cancer; cancer therapy; clinical feature; colon cancer; cytotoxicity; Echinococcus granulosus; helminth; human; immune system; immunomodulation; in vitro study; leukemia; medical information; melanoma; nonhuman; ovary cancer; pancreas cancer; regulatory T lymphocyte; survival rate; Taenia solium; therapy with helminths; Toxocara canis; Trichinella spiralis; tumor growth; tumor microenvironment
%R 10.54203/SCIL.2023.WVJ65
%P 606-616
%N 4